ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE

4CPS-259
ATC: J05

Gutiérrez-Lorenzo M[1], Urda-Romacho J[1], Rubio-Calvo D[1], Castro-Vida MA[1], Pinto-Nieto CM[1]
1: Agencia pública sanitaria Poniente (Almería), Hospital Pharmacy Service

BACKGROUND

Therapies for Human immunodeficiency virus (HIV) are continuously renewing. For these reason Antiretroviral treatment (ART) for HIV patients should be individualized. Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in fixed-dose combination is a new ART that has been approved.

AIM AND OBJECTIVES

To assess efficacy and safety at 24 weeks of BIC/FTC/TAF in naive patients and patients switching to BIC/FTC/TAF.

MATERIAL AND METHODS

DESING: observational retrospective study	**STUDY TIME:** 2019-2020	**PARTICIPANTS**: HIV patients (naïve or switching) treated with BIC/FTC/TAF for at least 24 weeks



RESULTS

95 patients were included

25 Naïve



Mean age: **40 years**

70 Switching



Mean age: **43 years**

Analytical data at BASELINE

Median VL	**764,026 copies/ml**	**Median VL**	**120,413 copies/ml**
Median CD4	**402 cells/ml**	**Median CD4**	**639 cells/ml**

Analytical data AFTER 24 WEEKS





SAFETY



None of these AE was a reason for treatment interruption

CONCLUSIONS

- ✓BIC/FTC/TAF Proved to be effective and safe in both naïve and switch patients
- ✓All AE reported during the study were mild and with a low incidence

Contact: Daniel.rubio@ephpo.es

Junta de Andalucía
Consejería de Salud y Familias
AGENCIA PÚBLICA SANITARIA PONIENTE

UGCI
UNIDAD DE GESTIÓN CLÍNICA INTERNIVELES
FARMACIA PONIENTE

eahp
european association of hospital pharmacists